AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28401352 — intervention group
Group type: COMPARATOR
Intervention: Routine-FKI
Number of subjects: 113
Study 24886871 — intervention group
Group type: EXPERIMENTAL
Intervention: Single freeze with N2O
Number of subjects: 60
Study 24886871 — intervention group
Group type: EXPERIMENTAL
Intervention: Single freeze with CO2
Number of subjects: 60
Study 24886871 — intervention group
Group type: COMPARATOR
Intervention: Double freeze with N2O
Number of subjects: 60
Study 23822518 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Ecologic®Barrier)
Number of subjects: 120
Study 23822518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 21795429 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown Rice (BR)
Number of subjects: 202
Study 21795429 — intervention group
Group type: COMPARATOR
Intervention: White Rice (WR)
Number of subjects: 202
Study 19362230 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar spine manipulation (experimental group, n = 13)
Number of subjects: 27
Study 19362230 — intervention group
Group type: COMPARATOR
Intervention: Side-lying control position (control group, n = 14)
Number of subjects: 27
Study 17531660 — intervention group
Group type: EXPERIMENTAL
Intervention: Defer group (n=91)
Number of subjects: 325
Study 17531660 — intervention group
Group type: EXPERIMENTAL
Intervention: Perform group (n=90)
Number of subjects: 325
Study 17531660 — intervention group
Group type: COMPARATOR
Intervention: Reference group (n=144)
Number of subjects: 325
Study 15465985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior treatment of residual symptoms (supplemented by lifestyle modification and well-being therapy)
Number of subjects: 40
Study 15465985 — intervention group
Group type: COMPARATOR
Intervention: Clinical management
Number of subjects: 40
Study 11176319 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g hyperimmune egg yolk (HEY) daily in four equally divided doses for 4 days
Number of subjects: 79
Study 11176319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonimmunized chicken preparation)
Number of subjects: 79
Study 10626096 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 15 mg/d for 3 weeks
Number of subjects: 16
Study 10626096 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 16
Study 7589820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with sulfonylurea or insulin
Number of subjects: 4209
Study 7589820 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy primarily with diet
Number of subjects: 4209
Study 7589820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with metformin
Number of subjects: 4209
Study 7589820 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy
Number of subjects: 4209
Study 7589820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy compared with conventional therapy
Number of subjects: 4209
Study 1770147 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (n = 16)
Number of subjects: 49
Study 1770147 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (n = 33) using transvaginal methotrexate or sulprostone injection
Number of subjects: 49
Study 1770147 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall follow-up for all patients
Number of subjects: 49
Study 1770147 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingography
Number of subjects: 49
Study 6982085 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified LSA2‐L2 multidrug regimen
Number of subjects: 53
Study 30285104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab every 8 weeks
Number of subjects: 373
Study 30285104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab every 4 weeks
Number of subjects: 373
Study 30285104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 29277297 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and isoflurane (Dex-Iso, n = 50)
Number of subjects: 97
Study 29277297 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane alone (Iso, n = 47)
Number of subjects: 97
Study 27782847 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive urodynamic testing
Number of subjects: 284
Study 27782847 — intervention group
Group type: COMPARATOR
Intervention: Basic clinical assessment with noninvasive tests
Number of subjects: 284
Study 24886449 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined wound and intraperitoneal local anesthetic (W + P)
Number of subjects: 220
Study 24886449 — intervention group
Group type: COMPARATOR
Intervention: No local wound anesthetic with intraperitoneal local anesthetic (NW + P)
Number of subjects: 220
Study 23585468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral psychotherapy combined with intramuscular (IM) 3‐monthly injections of triptorelin for 12 months (total of 4 injections)
Number of subjects: 0
Study 23585468 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with cognitive‐behavioral psychotherapy for 12 months (total of 4 injections)
Number of subjects: 0
Study 23585468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral psychotherapy combined with triptorelin
Number of subjects: 0
Study 23585468 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with cognitive‐behavioral psychotherapy
Number of subjects: 0
Study 20573223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium + Valproic Acid
Number of subjects: 0
Study 20573223 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium + Carbamazepine
Number of subjects: 0
Study 18277375 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L/d high-calcium mineral water (483 mg/L) for Group A
Number of subjects: 95
Study 18277375 — intervention group
Group type: COMPARATOR
Intervention: 1 L/d high-calcium mineral water (483 mg/L) for Group B1
Number of subjects: 95
Study 18277375 — intervention group
Group type: COMPARATOR
Intervention: 1 L/d placebo mineral water (Ca:80 mg/L) for Group B2
Number of subjects: 95
Study 18277375 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L/d high-calcium mineral water (483 mg/L) for Group B2 (after switching from placebo)
Number of subjects: 95
Study 15681008 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer for 20 s (Clearfil SE Primer) with Single Bond
Number of subjects: 0
Study 15681008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 M EDTA for 30 s with Clearfil SE Bond
Number of subjects: 0
Study 15681008 — intervention group
Group type: EXPERIMENTAL
Intervention: 37% phosphoric acid for 15 s with Single Bond
Number of subjects: 0
Study 15681008 — intervention group
Group type: COMPARATOR
Intervention: Other combinations (not specified)
Number of subjects: 0
Study 14618354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sekundo's slitlamp green light test
Number of subjects: 50
Study 14618354 — intervention group
Group type: COMPARATOR
Intervention: Colvard pupilometer
Number of subjects: 50
Study 14618354 — intervention group
Group type: COMPARATOR
Intervention: Comparison of methods
Number of subjects: 50
Study 10561363 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNalpha2a plus VLB
Number of subjects: 160
Study 10561363 — intervention group
Group type: COMPARATOR
Intervention: VLB alone
Number of subjects: 160
Study 8970247 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 926
Study 8970247 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 926
Study 8970247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 926
Study 1468826 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10-20 mg per day
Number of subjects: 24
Study 1468826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1468826 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study 6504945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg twice daily
Number of subjects: 292
Study 6504945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg twice daily
Number of subjects: 292
Study 6504945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of pivmecillinam
Number of subjects: 292
Study 30940355 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration injections
Number of subjects: 100
Study 30940355 — intervention group
Group type: COMPARATOR
Intervention: Infraorbital nerve block
Number of subjects: 100
Study 29034453 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-825 (22 mg sumatriptan nasal powder)
Number of subjects: 0
Study 29034453 — intervention group
Group type: COMPARATOR
Intervention: Oral sumatriptan (100 mg tablets)
Number of subjects: 0
Study 27454274 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone 0.5 mg/kg
Number of subjects: 90
Study 27454274 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal dexamethasone 0.1 mg/kg
Number of subjects: 90
Study 27454274 — intervention group
Group type: COMPARATOR
Intervention: Control group (IV normal saline)
Number of subjects: 90
Study 24823727 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain group (subdural drain inserted after burr-hole drainage)
Number of subjects: 200
Study 24823727 — intervention group
Group type: COMPARATOR
Intervention: Without drain group (no subdural drain inserted after burr-hole drainage)
Number of subjects: 200
Study 24823727 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 200
Study 24823727 — intervention group
Group type: COMPARATOR
Intervention: Without drain group
Number of subjects: 200
Study 23193843 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAAs)
Number of subjects: 88
Study 23193843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 20618100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided access with the patient in the flank position (Group 1)
Number of subjects: 60
Study 20618100 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided access with the patient in the prone position (Group 2)
Number of subjects: 60
Study 18396107 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive lowering of blood pressure (target systolic BP 140 mm Hg)
Number of subjects: 404
Study 18396107 — intervention group
Group type: COMPARATOR
Intervention: Standard guideline-based management of blood pressure (target systolic BP 180 mm Hg)
Number of subjects: 404
Study 18396107 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensive lowering of blood pressure
Number of subjects: 404
Study 18396107 — intervention group
Group type: COMPARATOR
Intervention: Standard guideline-based management of blood pressure
Number of subjects: 404
Study 15573384 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin symptom scale (WICS) for IC patients
Number of subjects: 30
Study 15573384 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin symptom scale (WICS) for healthy female controls
Number of subjects: 30
Study 12008175 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg/day
Number of subjects: 41
Study 12008175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 10493455 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck cooling using a Life Support Systems, Inc. Mark VII portable cooling system and a liquid cooling helmet for 30 minutes.
Number of subjects: 50
Study 10493455 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck cooling during winter studies.
Number of subjects: 50
Study 10493455 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck cooling during summer studies for male subjects.
Number of subjects: 50
Study 10493455 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck cooling during summer studies for female subjects.
Number of subjects: 50
Study 9199122 — intervention group
Group type: EXPERIMENTAL
Intervention: Program I - Individual, motivating instructions of tooth brushing with bacterial plaque coloring
Number of subjects: 255
Study 9199122 — intervention group
Group type: EXPERIMENTAL
Intervention: Program II - Expanded educational activity among children and parents
Number of subjects: 255
Study 9199122 — intervention group
Group type: EXPERIMENTAL
Intervention: Program III - Expanded educational activity and professional cleaning of teeth, sealing, and intensive conservative treatment
Number of subjects: 255
Study 8293692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin 75 mg/day (study group, n = 40)
Number of subjects: 84
Study 8293692 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n = 44)
Number of subjects: 84
Study 3565526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 19
Study 3565526 — intervention group
Group type: COMPARATOR
Intervention: Control hand (no splinting)
Number of subjects: 19
Study 31924234 — intervention group
Group type: EXPERIMENTAL
Intervention: Custodiol‐N
Number of subjects: 614
Study 31924234 — intervention group
Group type: COMPARATOR
Intervention: Custodiol®
Number of subjects: 614
Study 29360493 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month lifestyle intervention
Number of subjects: 156
Study 29360493 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study 29360493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 156
Study 27590263 — intervention group
Group type: EXPERIMENTAL
Intervention: B. catenulatum at 3 months
Number of subjects: 117
Study 27590263 — intervention group
Group type: EXPERIMENTAL
Intervention: B. breve at 1 week
Number of subjects: 117
Study 27590263 — intervention group
Group type: EXPERIMENTAL
Intervention: B. breve at 3 months
Number of subjects: 117
Study 25817050 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 25817050 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea
Number of subjects: 0
Study 23609777 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (daily oral Zn supplements for two months)
Number of subjects: 2
Study 23609777 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 2
Study 21787433 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFAS
Number of subjects: 80
Study 21787433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 80
Study 21787433 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + PUFAS
Number of subjects: 80
Study 21787433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19543667 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial warmth (42 degrees C)
Number of subjects: 32
Study 19543667 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 32
Study 19543667 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for warmth therapy
Number of subjects: 32
Study 19543667 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for transcutaneous electrical nerve stimulation
Number of subjects: 32
Study 16936149 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous C‐peptide infusion (dosage 1: 25 pmol . kg(‐1) . min(‐1) bolus followed by 5 pmol . kg(‐1) . min(‐1) continuous infusion; dosage 2: six times higher than dosage 1)
Number of subjects: 10
Study 16936149 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution (control)
Number of subjects: 10
Study 15238460 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/d for 12 months
Number of subjects: 40
Study 11182002 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with vinorelbine, paclitaxel, or gemcitabine plus cisplatin followed by concomitant chemoradiotherapy with the same agents and standard radiation (66 Gy)
Number of subjects: 187
Study 11182002 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy
Number of subjects: 187
Study 11182002 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 187
Study 11182002 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy
Number of subjects: 187
Study 10221358 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI) 50-200 mg daily
Number of subjects: 41
Study 10221358 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (CMI)
Number of subjects: 41
Study 8032080 — intervention group
Group type: EXPERIMENTAL
Intervention: Various premedications (Groups A, B, C, D)
Number of subjects: 120
Study 8032080 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray (Groups A and C)
Number of subjects: 120
Study 8032080 — intervention group
Group type: COMPARATOR
Intervention: Control group (C1, C2, C3) - non‐diabetic patients not endoscoped
Number of subjects: 120
Study 2480941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated regimen of 2500‐3000 cGy in 9 to 10 fractions
Number of subjects: 29
Study 2480941 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 600 cGy or 800 cGy
Number of subjects: 29
Study 2480941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated regimen
Number of subjects: 29
Study 2480941 — intervention group
Group type: COMPARATOR
Intervention: Single dose therapy
Number of subjects: 29
Study 2480941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 4866185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 6 mg daily
Number of subjects: 3
Study 4866185 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine 6 mg or 48 mg
Number of subjects: 3
Study 4866185 — intervention group
Group type: COMPARATOR
Intervention: High-dosage isoniazid
Number of subjects: 3
Study 29389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg/day
Number of subjects: 121
Study 29389068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg/day
Number of subjects: 121
Study 29389068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 26560898 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic asthma
Number of subjects: 546
Study 26560898 — intervention group
Group type: COMPARATOR
Intervention: Nonatopic asthma
Number of subjects: 546
Study 26560898 — intervention group
Group type: EXPERIMENTAL
Intervention: High total IgE (tIgE)
Number of subjects: 546
Study 26560898 — intervention group
Group type: COMPARATOR
Intervention: Low total IgE (tIgE)
Number of subjects: 546
Study 24630791 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue group (n = 86)
Number of subjects: 172
Study 24630791 — intervention group
Group type: COMPARATOR
Intervention: Hold group (n = 86)
Number of subjects: 172
Study 24630791 — intervention group
Group type: EXPERIMENTAL
Intervention: No DM group (n = 25)
Number of subjects: 172
Study 24630791 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue group (n = 25)
Number of subjects: 172
Study 24630791 — intervention group
Group type: COMPARATOR
Intervention: Hold group (n = 25)
Number of subjects: 172
Study 22933750 — intervention group
Group type: COMPARATOR
Intervention: Boiled white-fleshed sweet potatoes (WFSP) and a corn oil capsule
Number of subjects: 120
Study 22933750 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Number of subjects: 120
Study 22933750 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried orange-fleshed sweet potatoes (OFSP) and a corn oil capsule
Number of subjects: 120
Study 22933750 — intervention group
Group type: COMPARATOR
Intervention: Boiled white-fleshed sweet potatoes (WFSP) and a retinyl palmitate capsule
Number of subjects: 120
Study 20505660 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg modafinil (divided into three doses)
Number of subjects: 18
Study 20505660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18726829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 463
Study 18726829 — intervention group
Group type: COMPARATOR
Intervention: Metformin (2000 mg daily)
Number of subjects: 463
Study 15733508 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized limited asthma education program (30-min interactive program + 30-min discussion with asthma nurse)
Number of subjects: 97
Study 15733508 — intervention group
Group type: COMPARATOR
Intervention: Routine schedule for asthma outpatients (Control)
Number of subjects: 97
Study 12843214 — intervention group
Group type: COMPARATOR
Intervention: SPECT imaging after intravenous injection of hexamethylpropyleneamine oxime or ethylcysteinate dimer
Number of subjects: 29
Study 12843214 — intervention group
Group type: COMPARATOR
Intervention: SPECT imaging in LS+ patients
Number of subjects: 29
Study 12843214 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging in LS+ vs LS- patients
Number of subjects: 29
Study 12843214 — intervention group
Group type: COMPARATOR
Intervention: SPECT imaging in A- patients
Number of subjects: 29
Study 12843214 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging in A+ vs A- patients
Number of subjects: 29
Study 12843214 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT imaging in patients without atrophy
Number of subjects: 29
Study 10228126 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0
Study 10228126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2223528 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 27
Study 2223528 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (half-strength Moduretic: hydrochlorothiazide 25 mg + amiloride hydrochloride 2.5 mg)
Number of subjects: 27
Study 2223528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atenolol, hydrochlorothiazide, and amiloride hydrochloride
Number of subjects: 27
Study 2223528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2223528 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (atenolol or diuretic)
Number of subjects: 27
Study 2223528 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment
Number of subjects: 27
Study 2223528 — intervention group
Group type: COMPARATOR
Intervention: 24-hour ambulatory ECG monitoring
Number of subjects: 27
Study 80275 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (60 mg/m2 every 3 weeks)
Number of subjects: 27